Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Connect Tissue Res. 2017 May 19;59(2):129–146. doi: 10.1080/03008207.2017.1313248

Figure 6: Restricted inhibition of MAPK activity inhibits ASC mineralization.

Figure 6:

Panel A – Mineralization levels following treatment for the first 24 hours of induction with the indicated MAPK inhibitors was measured after 21 or 35 days of osteogenesis and compared with non-treated controls (ASC Mineralization Capacity, -fold change vs. OM/vehicle). Panel B – Inhibitors were also added for 7 days to induce cells either at the start of matrix synthesis (7–14 days) or matrix mineralization (14–21 days) and then OM induction continued until 21 days. The ERK1/2 inhibitor Tyrphostin was administered at concentrations affecting either ERK1 or ERK2. * indicates a significance difference (p<0.05; t-test) between groups. MAPK inhibitors not significantly affecting mineralization versus controls are not shown.